Compare Ginkgo Bioworks Holdings Inc (DNA) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Vale SA — how do they compare? Ginkgo Bioworks Holdings Inc trades at $9.03 (market cap $590.53M), while Vale SA trades at $14.57 (market cap $60.78B). The key difference: Vale SA is far larger — about 102.9× Ginkgo Bioworks Holdings Inc's market cap, and Vale SA pays a 8.63% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | VALE | |
|---|---|---|
Market Cap | $590.53M | $60.78B |
Sector | Health | Basic Materials |
52-Week High | $16.14 | $17.82 |
52-Week Low | $5.48 | $9.53 |
Enterprise Value | $627.78M | $77.70B |
Dividend Yield | — | 8.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
VALE trades at $14.18, down 1.94% for the day, amid a bearish technical signal and mixed earnings history. The company reported revenue of $38.40B in 2025 with a net income margin of 7.21%, while recent news highlights a $2.6B decarbonization investment and governance developments. Cash flow remains positive, with operating cash flow at $8.80B in 2025.
The outlook is cautious; while analyst consensus is a Buy with a $17.50 price target, fundamental pressures from declining profit margins and a high debt-to-asset ratio of 24.66% pose risks. Upside depends on commodity price stability and execution of strategic investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
